MAPT and Alzheimer disease: While this may be expected in a transgenic model where most cells are being impacted by transgene expression, this statement likely holds true in other models (i.e., α-synuclein PFF) and in human disease, as it does for AT8 tau-negative cells from AD brains compared to healthy controls28.